Coping with asthma through life management program
BehavioralParticipants will complete surveys, learn stress coping strategies, receive asthma education information, and obtain access local community financial resources.
NCT Number: NCT07044388
The purpose of this study is to determine if the Coping with Asthma through Life Management (CALM) intervention, designed to help Black adult with asthma cope with stress, is feasible and acceptable.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Asthma medication nonadherence is a major contributor to asthma morbidity and mortality in Black adults. Black adults with asthma reported that increased psychosocial stress (e.g., perceived discrimination, job stress, caregiver burden), health-related stress (e.g., concern about asthma control), and economic stress (e.g., economic strain) were barriers to asthma medication adherence and control. The study's hypothesis is that CALM, targeting multiple stressors specifically faced by Black adults with asthma, will be feasibly implemented in a health system, will be acceptable to program participants, and will be a potentially effective intervention to improve asthma medication adherence and asthma control.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will complete surveys, learn stress coping strategies, receive asthma education information, and obtain access local community financial resources.
Participants in this group will complete surveys but will not receive the CALM intervention. Upon completing the study after 12 weeks they will be able to complete the program if they would like the resources/materials to learn healthy stress coping strategies, asthma health education, and access to financial resources.
Time frame: 12 weeks
The FIM has four items and the total score ranges from 4 to 20, where a higher score indicates greater feasibility.
Time frame: 12 Weeks
The AIM has four items and the total score ranges from 4 to 20, where a higher score indicates greater acceptability.
Time frame: 12 Weeks
The IAM has four items and the total score ranges from 4 to 20, where a higher score indicates greater appropriateness.
Time frame: 1 week
The ACQ-6 is a six-question questionnaire used to assess asthma control, focusing on symptoms and rescue medication use. Scores range from 0 to 6, with lower scores indicating better asthma control. A score of 1.5 or higher suggests poorly controlled asthma.
Time frame: 1 month
The PSS-10 is a 10-item questionnaire that evaluates the degree to which an individual has perceived life as unpredictable, uncontrollable, and overloading over the previous month. Scores range from 0 to 40, with higher scores indicating higher levels of perceived stress.
Time frame: 2 weeks
The AQLQ-M is a 20-item self-administered questionnaire to measure quality of life in adults with asthma. Scores range from 20 to 100, with higher scores indicating a greater negative impact of asthma.
Time frame: 12 weeks
Contact information is provided by the study sponsor or research team.
Isaretta Riley, MD-MPH
CONTACT
TraNae Gibbs, BS
CONTACT
Duke University
Other
Coping With Asthma Throughout Life Management: CALM Program for African American Adult Patients With Asthma
Acronym: CALM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03504605
Asthma, Autoimmune Diseases
Sheffield, United Kingdom
View Trial DetailsNCT07728578
Asthma, Bronchial Diseases
Damietta, Egypt
View Trial DetailsNCT05776927
Asthma, Bronchial Diseases
View Trial DetailsNCT07712393
Asthma, Bronchial Diseases
View Trial Details